DECITABINE-PRIMED TANDEM CD19/CD20 CAR T CELLS

Clinical trials for DECITABINE-PRIMED TANDEM CD19/CD20 CAR T CELLS explained in plain language.

Never miss a new study

Get alerted when new DECITABINE-PRIMED TANDEM CD19/CD20 CAR T CELLS trials appear

Sign up with your email to follow new studies for DECITABINE-PRIMED TANDEM CD19/CD20 CAR T CELLS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Double-Targeting immune cells tested as potential lifeline for tough lymphomas

Disease control Ongoing

This study is testing a new type of CAR T-cell therapy for adults with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy uses a patient's own modified immune cells designed to attack two common targets on lymphoma cells (CD19 an…

Matched conditions: DECITABINE-PRIMED TANDEM CD19/CD20 CAR T CELLS

Phase: PHASE1, PHASE2 • Sponsor: Han weidong • Aim: Disease control

Last updated Mar 30, 2026 14:32 UTC

DECITABINE-PRIMED TANDEM CD19/CD20 CAR T CELLS

Get alerted when new DECITABINE-PRIMED TANDEM CD19/CD20 CAR T CELLS trials appear

Double-Targeting immune cells tested as potential lifeline for tough lymphomas